Morphine Sulfate
morphine sulfate (MS Contin, Kadian, Arymo ER, MorphaBond ER)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Moderate to severe acute pain (IR oral, injection) | Adults; pediatric varies by formulation | Opioid analgesic; monotherapy or as part of multimodal approach | FDA Approved |
| Severe chronic pain requiring continuous around-the-clock opioid (ER oral) | Opioid-tolerant adults | Around-the-clock; not for as-needed use; ER only for opioid-tolerant patients | FDA Approved |
| Neuraxial analgesia (epidural/intrathecal — preservative-free) | Adults | Perioperative and obstetric analgesia; single-dose or continuous infusion | FDA Approved |
Morphine remains the prototypical and reference-standard opioid analgesic against which all other opioids are compared. It is the cornerstone of the WHO analgesic ladder for cancer pain and is extensively used in acute postoperative pain, trauma, palliative care, and sickle cell vaso-occlusive crises. The availability of multiple formulations (immediate-release tablets and solutions, extended-release tablets and capsules, injectable solutions, suppositories, and preservative-free neuraxial preparations) allows individualized pain management across clinical settings from emergency departments to hospice care. Morphine is the gold standard for expressing opioid equianalgesic doses.
Acute dyspnea in heart failure and palliative care: Low-dose IV morphine (1–3 mg) is used for relief of dyspnea in acute decompensated heart failure and end-of-life care, though recent guidelines advise caution in acute HF due to potential harm signals. Evidence quality: Moderate (palliative); Low (acute HF).
Acute pulmonary edema: IV morphine has been traditionally used for anxiolysis and preload reduction, though current ESC guidelines de-emphasize its routine use. Evidence quality: Low.
Dosing
Parenteral Dosing (IV / IM / SC)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Acute severe pain — opioid-naive adult (IV) | 2–4 mg IV q3–4h | Titrate to effect q3–4h | No absolute ceiling; titrate to effect | Administer slowly over 4–5 min; onset 5–10 min IV Risk of respiratory depression highest in first 24–72 h |
| Acute pain — opioid-naive adult (IM/SC) | 5–10 mg IM/SC q3–4h | Titrate to effect | No absolute ceiling | IM absorption variable; SC preferred for continuous infusion in palliative care Oral:parenteral potency ratio ~3:1 to 6:1 (FDA PI) |
| Postoperative PCA — standard adult | 1 mg demand dose | 1–2 mg demand, 6–10 min lockout | Hourly max typically 6–10 mg | Background infusion generally not recommended for opioid-naive patients due to respiratory depression risk |
| Elderly or debilitated patients (IV) | 1–2 mg IV | Titrate cautiously | Individualize | Start at low end of dosing range; increased sensitivity to respiratory depression Beers Criteria: use with caution in older adults |
Oral Dosing — Immediate-Release (IR)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Moderate-to-severe pain — opioid-naive | 15–30 mg PO q4h | Titrate to adequate analgesia | No absolute ceiling | Oral bioavailability only 20–40% due to first-pass; may take with food Oral solution available: 10 mg/5 mL, 20 mg/5 mL, 100 mg/5 mL (opioid-tolerant only) |
| Conversion from parenteral morphine | 3–6× the parenteral dose | Adjust per response | Individualize | FDA PI: 3–6 mg oral morphine per 1 mg parenteral; use the lower end (3:1) when converting IV→oral and titrate upward Always underestimate and provide rescue medication |
Oral Dosing — Extended-Release (ER)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Chronic severe pain — opioid-naive (new to ER) | 15 mg PO q8–12h | Titrate q1–2 days | Individualize; no ceiling | Swallow whole; never crush/chew (fatal dose dump risk); ER 100/200 mg only for opioid-tolerant patients Steady state in ~1 day |
| Conversion from IR oral morphine to ER | Same total daily dose, divided q8–12h (or q24h for Kadian/Avinza) | Titrate per response | Individualize | Conversion may lead to peak sedation; start conservatively and provide IR rescue Provide IR morphine for breakthrough pain |
Neuraxial Dosing (Preservative-Free Only)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Epidural — postoperative/obstetric analgesia | 2–5 mg single dose | May repeat in 24 h if needed | 10 mg/24 h | Only ~5% crosses dura; monitor for respiratory depression ≥24 h after dose Must use preservative-free formulation |
| Intrathecal — surgical/obstetric analgesia | 0.1–0.3 mg single dose | Usually single dose | 1 mg | Monitor in fully equipped facility for ≥24 h; rostral spread causes delayed respiratory depression 100 mcg optimal balance of analgesia vs PONV for lower limb arthroplasty |
The oral-to-parenteral potency ratio for morphine ranges from approximately 3:1 to 6:1 according to the FDA prescribing information (i.e., 3–6 mg oral morphine to provide equivalent analgesia to 1 mg parenteral morphine). The conventional ratio used in most equianalgesic tables is 3:1 (30 mg oral ≈ 10 mg IV), which represents the lower end of this range. This variability reflects morphine’s extensive first-pass hepatic metabolism and substantial inter-individual differences in bioavailability (20–40%). When converting between routes, it is always safer to underestimate the oral dose and provide rescue medication than to overestimate. Consider reducing the calculated equianalgesic dose by 25–50% for incomplete cross-tolerance when switching opioids.
Pharmacology
Mechanism of Action
Morphine is a full agonist at the mu-opioid receptor (MOR), the primary mediator of its analgesic, euphoric, and respiratory depressant effects. It also activates kappa and delta opioid receptors to a lesser degree. Binding to mu-receptors in the brain, spinal cord dorsal horn, and peripheral nociceptors activates inhibitory G-proteins, leading to closure of voltage-gated calcium channels, opening of potassium channels, and suppression of cyclic AMP production. The net effect is reduced neuronal excitability and diminished transmission of nociceptive signals. In the gastrointestinal tract, mu-receptor activation on the myenteric plexus inhibits gastric emptying and peristalsis, producing the characteristic and persistent constipation. Morphine also causes histamine release from mast cells, contributing to pruritus, flushing, and bronchospasm in susceptible individuals — a property that distinguishes it from synthetic opioids like fentanyl.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability 20–40% (high inter-individual variability, 15–64% in cancer patients); Tmax ~1 h (IR oral); high first-pass hepatic extraction | Oral-to-parenteral ratio is approximately 3:1; wide variability means individual titration is mandatory; can be taken without regard to food |
| Distribution | Vd 1–6 L/kg (mean ~3 L/kg); protein binding 20–35% (albumin); crosses blood-brain barrier and placenta; milk-to-plasma AUC ratio ~2.5:1 | Low protein binding minimizes displacement interactions; substantial breast milk penetration limits use in nursing mothers; placental transfer contributes to neonatal withdrawal risk |
| Metabolism | Hepatic glucuronidation by UGT2B7: M3G (45–55% of dose, inactive) and M6G (10–15% of dose, active — more potent mu-agonist than morphine); minor N-demethylation via CYP3A4 to normorphine (~5%) | M6G contributes significantly to analgesia after oral dosing (higher M6G:morphine ratio orally vs IV); M3G and M6G accumulate dangerously in renal failure; glucuronidation preserved even in severe liver disease but bioavailability increases |
| Elimination | Effective t½ ~2–4 h (IV ~2 h); terminal t½ ~15 h; clearance 20–30 mL/min/kg; ~90% renal (~10% unchanged, 45–55% as M3G, 10–15% as M6G); 7–10% fecal; minor enterohepatic recycling | Short effective half-life means IR dosing q4h; terminal phase reflects slow release from tissue stores; renal impairment prolongs exposure to active M6G and can cause delayed respiratory depression |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Constipation | 40–95% | Does not habituate; proactive bowel regimen mandatory throughout therapy; mu-receptor mediated inhibition of peristalsis |
| Nausea | 15–40% | Usually resolves within 3–5 days due to tolerance at the chemoreceptor trigger zone; anti-emetic may be needed initially |
| Sedation/Drowsiness | 15–30% | Dose-related; tolerance typically develops within 3–7 days; more prominent in ambulatory patients |
| Dizziness/Lightheadedness | 10–20% | Partly related to orthostatic hypotension; warn about position changes; more common in ambulatory patients |
| Miosis | >90% | Near-universal at therapeutic doses; pupil constriction does not habituate; useful diagnostic sign of opioid effect |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Vomiting | 7–15% | CTZ-mediated; generally habituates with continued use; more common at treatment initiation |
| Pruritus | 5–10% | Histamine-mediated (oral/parenteral) and centrally mediated (neuraxial, up to 30%); antihistamines may help for systemic pruritus |
| Diaphoresis | 5–10% | Opioid class effect; not an indication of overdose at therapeutic doses |
| Urinary retention | 5–15% | Increased detrusor muscle tone and sphincter tone; more common with neuraxial administration and in elderly men |
| Dry mouth | 5–20% | Anticholinergic-like effect; encourage oral hydration and good dental care with chronic use |
| Euphoria/Dysphoria | 3–5% | Euphoria contributes to abuse potential; dysphoria more common in ambulatory patients without severe pain |
| Orthostatic hypotension | 3–5% | Due to peripheral vasodilation and histamine release; advise slow position changes; worse with hypovolemia |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Respiratory depression | Dose-dependent; highest in opioid-naive | First 24–72 h of therapy or after dose increase; delayed up to 24 h with neuraxial dosing | Naloxone 0.4–2 mg IV; airway support; dose reduction; monitor in equipped facility for neuraxial morphine |
| Severe hypotension / Circulatory depression | Uncommon | Within minutes (IV); exacerbated by hypovolemia or concurrent vasodilators | IV fluids, vasopressors if needed; reduce dose; avoid in circulatory shock |
| Anaphylactoid reactions | Rare | Usually with IV administration; related to histamine release | Epinephrine, airway management; slow injection rate minimizes risk |
| Serotonin syndrome | Rare | Hours to days after addition of serotonergic agent | Discontinue all serotonergic agents; cyproheptadine; supportive care |
| Adrenal insufficiency | Rare; with chronic use | After ≥1 month of use | Cortisol testing; taper opioid; physiologic steroid replacement |
| Neonatal opioid withdrawal syndrome | Expected with prolonged maternal use | Hours to days after delivery | Neonatal monitoring; supportive care; do not abruptly discontinue in pregnant patients |
Unlike most morphine side effects (nausea, sedation, dizziness), constipation does not improve with tolerance. Proactive prevention is essential from day one. A stepped approach is recommended: start a stimulant laxative (senna or bisacodyl) with or without a stool softener (docusate) at initiation of morphine therapy. If inadequate, add an osmotic agent (polyethylene glycol or lactulose). For opioid-induced constipation refractory to conventional laxatives, peripherally acting mu-opioid receptor antagonists (PAMORAs) such as naloxegol or methylnaltrexone may be considered. Counsel patients that constipation management is a required component of opioid therapy, not an optional one.
Drug Interactions
Morphine’s primary metabolism via UGT2B7 glucuronidation rather than CYP450 means its pharmacokinetic interaction profile is simpler than many opioids. However, pharmacodynamic interactions — particularly additive CNS and respiratory depression — are the dominant clinical concern and carry boxed-warning status.
Monitoring
- Respiratory StatusContinuous at initiation
RoutineMonitor respiratory rate, oxygen saturation, and level of sedation, especially during first 24–72 h, after dose increases, and for ≥24 h after neuraxial administration. RASS or similar sedation scale recommended. - Pain AssessmentEach visit/dose interval
RoutineValidated pain scale at each assessment. For chronic use, re-evaluate risk-benefit at least every 3 months. Document functional outcomes alongside pain scores. - Bowel FunctionEach visit
RoutineInitiate preventive bowel regimen at day 1. Assess stool frequency and consistency at every visit. Constipation does not improve with tolerance and can lead to obstruction. - Signs of Misuse / OUDEach visit
RoutineCheck PDMP before prescribing and periodically. Screen for aberrant behaviors. Risk assessment (ORT or SOAPP-R) at baseline. Urine drug testing as clinically indicated. - Renal FunctionBaseline; periodically
RoutineM3G and M6G accumulate in renal impairment, increasing risk of prolonged sedation and delayed respiratory depression. Serum creatinine and eGFR at baseline and periodically in chronic use. - Hepatic FunctionBaseline if impaired
Trigger-basedCirrhosis increases oral bioavailability and prolongs half-life; dose reduction and careful titration required. - Endocrine FunctionIf symptoms arise
Trigger-basedChronic opioid use inhibits ACTH, cortisol, and gonadotropins. Assess for adrenal insufficiency and hypogonadism if fatigue, weakness, or sexual dysfunction develop.
Contraindications & Cautions
Absolute Contraindications
- Significant respiratory depression — in settings without monitoring or resuscitative equipment
- Acute or severe bronchial asthma — in unmonitored settings or without resuscitative equipment
- Known or suspected GI obstruction, including paralytic ileus
- Hypersensitivity to morphine — anaphylactoid reactions reported with IV phenanthrene alkaloids
- Concurrent use of MAO inhibitors or within 14 days
Relative Contraindications (Specialist Input Recommended)
- Severe renal impairment — M6G accumulation can cause prolonged and delayed respiratory depression; consider alternative opioid (hydromorphone or fentanyl)
- Severe hepatic impairment (cirrhosis) — bioavailability increases substantially; reduce dose and extend intervals
- History of substance use disorder — Schedule II; high abuse potential; rigorous risk assessment required
- Head injury or raised intracranial pressure — CO2 retention elevates ICP; miosis obscures neurological assessment
Use with Caution
- Elderly or debilitated patients — increased sensitivity to respiratory depression; start low and titrate slowly
- Biliary tract disease / pancreatitis — sphincter of Oddi spasm may worsen biliary colic
- Hypothyroidism, Addison’s disease — enhanced opioid sensitivity
- Prostatic hypertrophy or urethral stricture — increased urinary retention risk
- COPD or cor pulmonale — reduced respiratory reserve increases risk of fatal respiratory depression
Addiction, abuse, and misuse: Morphine exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk before prescribing.
Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially during initiation or dose escalation. ER formulations pose additional risk due to higher drug content.
Accidental ingestion: Accidental ingestion of even one dose, especially by children, can result in fatal morphine overdose.
Neonatal opioid withdrawal syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated.
Concomitant use with benzodiazepines or other CNS depressants: Concomitant use may result in profound sedation, respiratory depression, coma, and death. Reserve concurrent prescribing for patients with no adequate alternatives.
ER/LA formulations — REMS: Ensure REMS compliance for ER/LA opioid analgesics.
Patient Counselling
Purpose of Therapy
Morphine is a strong opioid medication used to manage moderate to severe pain. It works by binding to natural pain receptors in your brain and spinal cord. When used correctly and under medical supervision, morphine is effective for controlling pain that has not responded to milder painkillers. However, it carries significant risks, including dependence, respiratory depression, and the potential for misuse. Your prescriber has determined that the expected benefit of morphine outweighs these risks for your specific situation.
How to Take
Take morphine exactly as prescribed. For immediate-release tablets or liquid, take the prescribed dose every 4 hours as directed. For extended-release tablets or capsules, take the prescribed dose every 8, 12, or 24 hours (depending on the formulation) at the same time(s) each day. Swallow extended-release formulations whole — never crush, break, or chew them, as this can release a dangerous amount at once. You may take morphine with or without food. Store all morphine products securely, out of reach of children and others.
Sources
- Morphine Sulfate Tablets — FDA-Approved Prescribing Information. accessdata.fda.govPrimary reference for oral IR dosing, adverse reactions, contraindications, boxed warnings, and pharmacokinetics including clearance, half-life, and renal/hepatic adjustments.
- Morphine Sulfate Oral Solution — FDA-Approved Prescribing Information. accessdata.fda.govSource for oral solution dosing, concentrated formulation restrictions (opioid-tolerant only), and conversion guidelines.
- MorphaBond ER (morphine sulfate) Extended-Release Tablets — FDA-Approved Prescribing Information. accessdata.fda.govReference for ER dosing, oral bioavailability (20–40%), steady-state achievement, and abuse-deterrent properties.
- Morphine Sulfate Injection — FDA-Approved Prescribing Information. accessdata.fda.govSource for parenteral dosing, IV/IM/SC administration guidance, adverse reactions with injection, and neuraxial warnings.
- Bercovitch M, Adunsky A. Patterns of high-dose morphine use in a home-care hospice service. Cancer. 2004;101(6):1473–1477. doi:10.1002/cncr.20515Study documenting side effect prevalence (constipation, dry mouth, sedation) with individualized morphine dosing in hospice patients.
- Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain — an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7(7):CD012592. doi:10.1002/14651858.CD012592.pub2Cochrane overview establishing the evidence base for morphine in cancer pain management with documentation of typical adverse effect profiles.
- Bauchat JR, Weiniger CF, Sultan P, et al. SOAP Consensus Statement: monitoring recommendations for neuraxial morphine for cesarean delivery analgesia. Anesth Analg. 2019;129(2):458–474. doi:10.1213/ANE.0000000000004195Society consensus statement on monitoring protocols following neuraxial morphine, including respiratory depression surveillance timeframes.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(No. RR-3):1–95. doi:10.15585/mmwr.rr7103a1Current CDC guideline on opioid prescribing; provides dosing thresholds (MME), monitoring recommendations, and risk mitigation strategies applicable to morphine.
- American Geriatrics Society 2023 Updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052–2081. doi:10.1111/jgs.18372Classifies opioids including morphine as potentially inappropriate in older adults due to risk of falls, fractures, and respiratory depression.
- WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: World Health Organization; 2018. who.intWHO guideline placing morphine as the first-choice strong opioid for moderate-to-severe cancer pain in the analgesic ladder framework.
- Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand. 1997;41(1 Pt 2):116–122. doi:10.1111/j.1399-6576.1997.tb04625.xKey review of M3G and M6G pharmacology, establishing that M3G constitutes 45–55% and M6G 10–15% of morphine metabolism, with M6G as an active analgesic metabolite.
- Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev. 2005;25(5):521–544. doi:10.1002/med.20035Comprehensive review of M6G pharmacodynamics, confirming its greater potency than morphine at the mu-opioid receptor and clinical significance of renal accumulation.
- Hasselström J, Säwe J. Morphine pharmacokinetics and metabolism in humans: enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet. 1993;24(4):344–354. doi:10.2165/00003088-199324040-00007Definitive PK study establishing oral bioavailability (~29%), clearance (21.1 mL/min/kg), volume of distribution (2.9 L/kg), and the ~15-hour terminal half-life.
- Hasselström J, Eriksson S, Persson A, et al. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990;29(3):289–297. doi:10.1111/j.1365-2125.1990.tb03638.xKey study demonstrating increased oral bioavailability (up to 101%) and prolonged half-life (4.2 h vs 2–3 h) in severe cirrhosis, informing dose adjustments.
- Morphine — StatPearls [Internet]. National Library of Medicine. Updated September 29, 2025. ncbi.nlm.nih.govComprehensive clinical reference covering all formulations, dosing, mechanism, CYP/UGT metabolism, special populations, and current FDA labeling updates.